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esponsibility of InstAbstract The prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide has increased at an alarming
rate, which will likely result in enormous medical and economic burden. NAFLD presents as a spectrum of liver
diseases ranging from simple steatosis, nonalcoholic steatohepatitis (NASH), ﬁbrosis, cirrhosis, and even to
hepatocellular carcinoma (HCC). A comprehensive understanding of the mechanism(s) of NAFLD-to-NASH
transition remains elusive with various genetic and environmental susceptibility factors possibly involved. An
understanding of the mechanism may provide novel strategies in the prevention and treatment to NASH.
Abnormal regulation of bile acid homeostasis emerges as an important mechanism to liver injury. The bile acid
homeostasis is critically regulated by the farnesoid X receptor (FXR) that is activated by bile acids. FXR has been
known to exert tissue-speciﬁc effects in regulating bile acid synthesis and transport. Current investigations
demonstrate FXR also plays a principle role in regulating lipid metabolism and suppressing inﬂammation in the
liver. Therefore, the future determination of the molecular mechanism by which FXR protects the liver from
developing NAFLD may shed light to the prevention and treatment of NAFLD.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.
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Yan Zhu et al.4101. Introduction to nonalcoholic fatty liver disease (NAFLD),
nonalcoholic steatohepatitis (NASH), and liver lipid
metabolism
The prevalence of NAFLD worldwide has increased at an
alarming rate with 30%–40% estimated in developed countries,
and this global liver disease will result in enormous medical and
economic burden1. NAFLD presents as a spectrum of liver
diseases initiated with excess accumulation of lipids in the
hepatocytes in the absence of excess alcohol consumption.
Although many NALFD cases are benign in prognosis, it is
estimated that some cases will progress from simple steatosis to
NASH, ﬁbrosis, cirrhosis and even hepatocellular carcinoma
(HCC). NASH comprises dysregulation of lipid metabolism and
increased inﬂammation, but a comprehensive understanding of
the mechanism(s) of NAFLD-to-NASH transition remains
elusive. Therefore, identiﬁcation of the various genetic and
environmental factors that contribute to the increased suscept-
ibility to NASH may provide novel treatments to limit inﬂam-
mation and ﬁbrosis in NAFLD patients.
A considerable amount of efforts has been devoted to understand
the mechanisms underlying simple steatosis-to-NASH transition. The
most widely accepted theories are the “two-hit” and “multiple-hit”
theories2,3. A common proposal in both theories is the acknowl-
edgments of the secondary factors related to lipid/cholesterol
metabolism and inﬂammation that precipitate NASH in NAFLD
patients are critical in the transition from simple steatosis to NASH.2. Bile acids
Bile acids are synthesized from cholesterol in the liver and the
enzymatic pathways have been well deﬁned over the last 60
years4. There are two major pathways to synthesize bile acids—
one is the classical or neutral pathway, initiated with the enzymatic
reaction of cholesterol-7α-hydroxylase (CYP7A1), and the other
one is the alternative or acidic pathway initiated by CYP27A1.
The classical pathway produces cholic acid (CA) and the alter-
native pathway generates chenodeoxycholic acid (CDCA). In
rodents and other species, CDCA is rapidly converted to more
hydrophilic forms of bile acids in the liver, such as muricholic acid
(MCA) or ursodeoxycholic acid (UDCA). In addition to CYP7A1
and CYP27A1, there are at least two other pathways that lead to
bile acid production involving cholesterol 24 and 25 hydroxyla-
tion. CA-, CDCA-, and UDCA-derived bile acids are termed
primary bile acids that are conjugated in the liver to taurine or
glycine. The conjugated bile acids are excreted into the bile, and,
in the intestine, the intestinal microﬂora de-conjugate the primary
bile acids and remove a hydroxylated group, generating secondary
bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA).
Bile acids have been important during evolution and maybe
undergone a variety of modiﬁcations5. Bile acids have been shown
to not only serve as detergent in facilitating the intestinal
absorption of lipids and lipid-soluble vitamins (vitamins A, D,
K, and E), they are also critical in mediating cellular and molecular
signals via activating nuclear receptors, FXR, pregnane X receptor,
and vitamin D receptor, as well as G-protein coupled bile acid
receptors, TGR5, and sphingosin-1-phosphate receptor 26. The
revealed roles of bile acids in regulating liver functions, intestinal
health, and systemic homeostasis are diverse.3. FXR and tissue-speciﬁc roles of FXR in regulating bile
acid homeostasis
The FXR gene (NR1H4/Nr1h4) was cloned in 19957 and in 1999,
bile acids were identiﬁed as endogenous ligands of FXR with
CDCA being the strongest endogenous ligand8–10. The generation
of Fxr knockout (KO) mice has accelerated the research of the
roles of FXR in physiology and pathology11. FXR deﬁciency in
mice renders the animals to cholestasis11, disrupted cholesterol
homeostasis12, susceptibility to atherosclerosis in a gender-
dependent manner13, partial failure in liver regeneration14,15,
spontaneous HCC16,17, increased NASH development18, and an
elevated susceptibility to colon cancer formation19. Down-
regulation of FXR expression and function has also been reported
in human HCC and colon cancer20,21. The underlying mechanisms
by which FXR regulates these pathological processes appear to be
due to either FXR-mediated, direct transcriptional regulation of
critical mediators in the disease development, or via improving
bile acid homeostasis, as increased bile acid levels have been
shown to promote inﬂammation and tumorigenesis.
FXR exerts bile-acid regulatory effects via a tissue-speciﬁc
mechanism. The activation of FXR in the liver and more critically,
in the intestine, is critical in the feedback suppression of bile acid
synthesis22–25. In the intestine, activation of FXR induces the
expression of an endocrine ﬁbroblast growth factor 15 (FGF15,
human homolog, FGF19), and the increased expression of FGF15
has been shown to mediate direct effects on suppressing bile acid
synthesis and promote hepatic health23,24,26.4. Tissue speciﬁc roles of FXR in regulating lipid metabolism
and inﬂammation
The tissue speciﬁc effects of FXR have provided an interesting
perspective to study liver-intestine axis24,27. Clear tissue-speciﬁc
roles of FXR have been proposed by genome-wide DNA ChIP-seq
technology in mice28. It is very interesting to observe that there is
only 11% overlap between FXR-binding sites between the liver
and intestine, indicating underlying molecular mechanism of
tissue-speciﬁc regulation by FXR activation. Furthermore, the
annotated pathways in the liver and intestine predict differential
functions of FXR in the liver and intestine. The detailed clariﬁca-
tion of FXR functions in liver and intestine awaits further research.
The human FXR genome-wide binding has been reported which
supports the view that mice can be used as a model to study human
FXR functions, particularly in diseases involved in lipid dysregu-
lation and inﬂammation29. This is because the comparison between
FXR genome-wide binding in mouse livers and in human primary
hepatocytes reveals that FXR regulates a few conservative path-
ways in both species. FXR activation has been known to reduce
triglyceride levels via suppressing de novo synthesis and uptake of
fatty acids in the liver30, and recently, the roles of FXR in reducing
inﬂammation have been emerging31. The FXR expression and
function were reduced during acute phase response32. FXR
activation strongly induced the expression of genes involved in
anti-inﬂammation, such as kininogen33, facilitated the suppression
of C-reactive protein production by interleukin 6 (IL-6)34, inhib-
ited smooth muscle inﬂammation35, suppressed nuclear factor κB
(NF-κB) activation in the liver36, reduced liver injury during
systemic lupus erythematosus37, decreased inﬂammation induced
Figure 1 Proposed roles of hepatic FXR in anti-inﬂammation in the
liver. FXR may exert its anti-inﬂammatory effects via (1) antagonizing
NF-κB function; (2) maintaining bile acid homeostasis; and (3) indu-
cing acute phase response proteins.
Fatty liver diseases, bile acids, and FXR 411by myoﬁbroblasts38, induced acute phase proteins39, and decreased
inﬂammation in the intestine40. In the liver, the molecular
mechanism by which FXR antagonizes inﬂammation may be
due to a acetyl/small ubiquitin-like modiﬁer (SUMO) switch so
that SUMOylation of FXR increased FXR's ability to suppress
NF-κB–mediated transcriptional induction of inﬂammatory
genes41. But the role of FXR in inﬂammation has also been
reported to be controversial42, perhaps reﬂecting the complexity of
FXR in modulating inﬂammation and immune function under
different diseases and/or different disease stages. The roles of FXR
in the ﬁght against liver inﬂammation have been summarized in
Fig. 1.5. Future perspectives
Recently, a role of tissue-speciﬁc FXR functions in regulating fatty
liver disease is emerging. It is reported that intestinal antagonism
of FXR function inhibits sterol regulatory element-binding protein-
1c (SREBP-1c) function by reducing the production of ceramide in
the intestine43,44, indicating that intestinal inhibition/antagonism of
FXR may present a promising opportunity in the treatment of liver
steatosis. However, intestine-speciﬁc activation of FXR led to
enhanced adipose tissue browning, which increased insulin sensi-
tivity and reduced obesity45. These conﬂicting, interesting reports
prompt further detailed studies of FXR's tissue speciﬁc effects on
fatty liver formation, NASH development and metabolic syndrome
progression. The recent development of FXR synthetic modulators
in the treatment of NASH and cholestasis also urge us to careful
deﬁne the functions of FXR in a tissue (cell)-speciﬁc, as well as
species-dependent, manner.
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